Overview

A Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822) in Healthy Volunteers

Status:
Completed

Trial end date:
2008-08-01

Target enrollment:

Participant gender:

Summary

This study assessed the safety, tolerability, and pharmacokinetics of single-dose odanacatib (MK0822) with and without food.

Phase:

Phase 1

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.